Top News

2021-01-04

Registration is now open; “Dynamic 3D tissue research workshop #2”: Jan.15

We are pleased to announce a series of four online seminars featuring talks by leading researchers in 3D tissue research and the current state of commercialization in start-up companies. We look forward to seeing you at this event.

Seminar Schedule (tentative)

Second session: Friday, January 15, 2021, Prof. Nagamori, Osaka Institute of Technology / Knowledge Palette Inc.

Third session: Mid-February 2021 Researcher (details will coming soon) / Thinkcyte, Inc.

Fourth Session: Mid-March 2021 Prof. Takeuchi, The University of Tokyo, Startup (details will coming soon)

Click here for the event site and registration



2020-12-29

Hidetoshi Hoshiya has been appointed as a new board director.

Hidetoshi Hoshiya has been appointed as a new board director as of December 1, 2020.

Dr. Hoshiya has more than 15 years of experience in the field of regenerative medicine, cell and gene therapy, having served for more than four years as the manager for Asia and Oceania at the Cell and Gene Therapy Catapult, a regenerative medicine industrialization organization in the UK.
Utilizing Dr. Hoshiya’s experience and knowledge in the industrialization of cell therapy, we will greatly accelerate the clinical application of high production cell culture technology.

Hidetoshi HoshiyaBiography
Graduated from Tottori University in 2009. PhD in Regenerative Medicine, is a Fellow of the Royal Society of Arts and a member of the Royal Society of Biology.
D. in Regenerative Medicine at Tottori University, San Raffaele Scientific Institute (Italy), University College London and Queen Mary University (UK). In November 2019, he became an independent consultant for startups, non-profit organizations, and major pharmaceutical companies. In December 2020, he was appointed to the board of CellFiber. He has more than 15 years of experience in the fields of regenerative medicine, cell and gene therapy.

Comment from Hidetoshi Hoshiya
I believe that CellFiber’s technology has the potential to become the golden standard for mass production of regenerative medical products, including cell and gene therapies. We will do our best to provide highly effective and safe regenerative medical products to patients quickly and inexpensively.

2020-12-15

Representative Director/CAO, Aki Adachi will appear on a online distribution program.

Our Representative Director / CAO, Aki Adachi, will appear on “the SOCIAL” (a news program for online viewing by Nippon Television Network Corporation), which will be broadcasted from noon on December 21, 2020. Please check it out!

the SOCIAL website

2020-12-08

Registration is now open; “Dynamic 3D tissue research workshop”

We are pleased to announce a series of four online seminars featuring talks by leading researchers in 3D tissue research and the current state of commercialization in start-up companies. We look forward to seeing you at this event.

Seminar Schedule (tentative)

First Session: Monday, December 21, 2020, 18:00-19:00 Prof. Onoe, Keio University / CellFiber Co., Ltd.

Second session: Mid-January 2021 Prof. Nagamori, Osaka Institute of Technology / Knowledge Palette Inc.

Third session: Mid-February 2021 Researcher (details will coming soon) / Thinkcyte, Inc.

Fourth Session: Mid-March 2021 Prof. Takeuchi, The University of Tokyo, Startup (details will coming soon)

Click here for the event site and registration

2020-12-08

A collaboration research project with TOYOBO was launched

We have been working on the R&D of high-producing cell culture and material production technologies. We have started joint research with TOYOBO from October 2020. We plan to complete technical evaluations in small-scale trials with several companies and proceed to joint development as needed.